Ranbaxy: Attracting attention - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Ranbaxy: Attracting attention

Sep 2, 2000

Ranbaxy has started to attract the marketís attention again. The stock has gone up by almost 15% over the last month. This despite the company declaring uninspiring results in the first half of the current year.

Uninspiring first half
(Rs) 1HFY99 1HFY00 Change
Sales 7,614 8,142 6.9%
Other Income 35 27 -22.9%
Expenditure 6,351 7,072 11.4%
EBDIT 1,263 1,070 -15.3%
OPM 16.6% 13.1%
Interest 112 7 -93.8%
Depreciation 219 247 12.8%
PBT 967 843 -12.8%
Tax 48 55 14.6%
PAT 919 788 -14%
NPM 12.1% 9.7%
No of shares 116 116
EPS 16 14

Despite a 7% rise in the turnover the companyís net profit has fallen marginally. The reasons for this are not far to seek. Ranbaxy depends a lot on antibiotics with almost 40% of the companyís domestic turnover accruing from this segment. With the segment witnessing heavy competition from unbranded generics, the companyís turnover growth as well as margins have been under strain.

Why then has the stock risen? The market seems to have taken note of an impending $ 5 mn (approximately Rs 225 m) payment receivable from Bayer that is likely to come in the third quarter of the current year.

Also, the company, at an analysts presentation in October 1999 had mentioned that the company was conducting phase I trials for a new chemical entity 'Parvosin' (codenamed RBx 2258) which was for Benign Prostrate Hyperplasia. Dr Brian Tempest, President Ranbaxy Pharmaceutical has also given a statement to the effect that Parvosin is to be launched shortly.

The management in its analysts presentation had also specified that there are three other molecules, one of which was RBx 4638 for respiratory diseases. It is quite possible that some announcement is expected from the company soon.

A further rise in the stock would depend on a positive announcement in the coming month.

Equitymaster requests your view! Post a comment on "Ranbaxy: Attracting attention". Click here!


More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Apr 1, 2015 (Close)


  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks